Published in J Clin Oncol on July 26, 2004
Role of retinoic receptors in lung carcinogenesis. J Exp Clin Cancer Res (2008) 0.81
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res (2005) 7.34
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res (2003) 4.22
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell (2011) 2.61
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res (2002) 2.50
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res (2005) 2.43
Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin (2011) 2.42
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell (2012) 2.39
Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst (2004) 2.38
Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst (2003) 2.31
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
Translation of innovative designs into phase I trials. J Clin Oncol (2007) 2.30
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev (2006) 2.22
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol (2009) 2.15
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst (2004) 2.13
Head and neck cancer chemoprevention gets a shot in the arm. J Clin Oncol (2008) 2.09
International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol Rev (2006) 2.04
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res (2008) 2.01
Perspectives for cancer prevention with natural compounds. J Clin Oncol (2009) 1.99
Cancer prevention with natural compounds. Semin Oncol (2010) 1.98
Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res (2006) 1.94
Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer (2012) 1.94
Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res (2006) 1.85
Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst (2007) 1.79
Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Semin Cancer Biol (2006) 1.78
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst (2003) 1.75
Examining the role of mitochondrial respiration in vanilloid-induced apoptosis. J Natl Cancer Inst (2002) 1.71
Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) (2009) 1.71
PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biol Ther (2007) 1.71
New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin Cancer Res (2005) 1.70
Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res (2009) 1.70
Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol (2002) 1.66
High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila) (2009) 1.59
Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. J Natl Cancer Inst (2007) 1.58
Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) (2009) 1.57
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila) (2013) 1.56
Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol (2007) 1.54
Mechanisms underlying the induction of the putative human tumor suppressor GPRC5A by retinoic acid. Cancer Biol Ther (2009) 1.54
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol (2013) 1.54
Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) (2011) 1.53
Contrast agents for confocal microscopy: how simple chemicals affect confocal images of normal and cancer cells in suspension. J Biomed Opt (2002) 1.53
p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J Clin Invest (2010) 1.50
Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res (2008) 1.50
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol (2002) 1.50
Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib. Cancer Biol Ther (2004) 1.49
Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci U S A (2007) 1.49
Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer (2004) 1.47
Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations. Cancer Biol Ther (2005) 1.47
Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol (2008) 1.43
Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. Mol Cell Biol (2011) 1.42
Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. J Biol Chem (2010) 1.40
Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis (2002) 1.39
Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control (2003) 1.39
Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology (2009) 1.39
14-3-3 proteins as potential therapeutic targets. Semin Cell Dev Biol (2011) 1.38
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther (2008) 1.36
Detection of circulating tumor cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles. Cancer Res (2011) 1.36
Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data. Cancer (2012) 1.33
The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther (2007) 1.33
Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res (2004) 1.32
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res (2003) 1.32
Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res (2009) 1.32
p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res (2004) 1.30
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res (2004) 1.30
The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. J Biol Chem (2009) 1.30
2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. Mol Cancer Ther (2008) 1.29
Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol Sci (2013) 1.29
Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. Mol Cancer Ther (2009) 1.28
LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. Cancer Res (2008) 1.28
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res (2005) 1.28
Depletion of intracellular glutathione contributes to JNK-mediated death receptor 5 upregulation and apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me). Cancer Biol Ther (2006) 1.27
Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin Cancer Res (2004) 1.27
Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res (2002) 1.26
The tumor suppressor LKB1 regulates lung cancer cell polarity by mediating cdc42 recruitment and activity. Cancer Res (2008) 1.26
Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res (2002) 1.26
Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol (2004) 1.25
Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation. Cancer Res (2008) 1.25
Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol (2008) 1.25
Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells. Cancer Res (2006) 1.24
Prevention of head and neck cancer: current status and future prospects. Curr Probl Cancer (2004) 1.24
Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene (2004) 1.21
Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat Rev (2003) 1.21
A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res (2010) 1.21
Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol Ther (2009) 1.21
HPV positive squamous cell carcinoma of the oropharynx. Are we observing an unusual pattern of metastases? Head Neck Pathol (2012) 1.21
Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res (2006) 1.20
The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. PLoS One (2011) 1.19